These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 20951552)

  • 1. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
    Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND
    Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
    Kendall KA; Leonard RJ
    J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
    Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
    J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
    Simpson CB; Lee CT; Hatcher JL; Michalek J
    Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voice handicap index results for older patients with adductor spasmodic dysphonia.
    Wingate JM; Ruddy BH; Lundy DS; Lehman J; Casiano R; Collins SP; Woodson GE; Sapienza C
    J Voice; 2005 Mar; 19(1):124-31. PubMed ID: 15766857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
    Young DL; Halstead LA
    J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
    Mendelsohn AH; Berke GS
    Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of the Voice Handicap Index-10 (VHI-10) and Voice-Related Quality of Life (V-RQOL) in patients with dysphonia.
    Romak JJ; Orbelo DM; Maragos NE; Ekbom DC
    J Voice; 2014 Mar; 28(2):237-40. PubMed ID: 24321582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined modality treatment of adductor spasmodic dysphonia.
    Silverman EP; Garvan C; Shrivastav R; Sapienza CM
    J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.
    Tsuji DH; Takahashi MT; Imamura R; Hachiya A; Sennes LU
    J Voice; 2012 Sep; 26(5):666.e7-12. PubMed ID: 21940146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
    Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
    J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abductor paralysis after botox injection for adductor spasmodic dysphonia.
    Venkatesan NN; Johns MM; Hapner ER; DelGaudio JM
    Laryngoscope; 2010 Jun; 120(6):1177-80. PubMed ID: 20513036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
    van Esch BF; Wegner I; Stegeman I; Grolman W
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency and Cutoff Values of Self-Assessment Instruments on the Impact of a Voice Problem.
    Behlau M; Madazio G; Moreti F; Oliveira G; Dos Santos Lde M; Paulinelli BR; Couto Junior Ede B
    J Voice; 2016 Jul; 30(4):506.e9-506.e18. PubMed ID: 26168902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal variations of laryngeal overpressure and voice-related quality of life in spasmodic dysphonia.
    Yeung JC; Fung K; Davis E; Rai SK; Day AM; Dzioba A; Bornbaum C; Doyle PC
    Laryngoscope; 2015 Mar; 125(3):661-6. PubMed ID: 25290557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.